spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:   diabetic nephropathy 

 HSMN NewsFeed - 29 Jan 2018
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2017
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Nov 2017
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 20 Jul 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2016
Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2014
Genkyotex Announces New Senior Management and Board Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2013
ChemoCentryx Announces GlaxoSmithKline's Release of Top-Line Results From the SHIELD-1 Phase III Study of Vercirnon
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 Nov 2010
Interim Results From Independent Study of H.P. Acthar(R) Gel in Patients With Advanced Diabetic Nephropathy Presented at American Society of Nephrology 43rd Annual Meeting
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Aug 2008
Pharmacopeia Announces Further Reductions to Workforce
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2008
Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2008
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 7 Mar 2008
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 28 Feb 2008
Pharmacopeia Announces Management Team Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2008
Keryx Biopharmaceuticals Announces Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2008
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 18 Jan 2008
GSK Does Not Option XL784 for Further Development
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 15 Oct 2007
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Sep 2007
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2007
William P. Kane Named Vice President, Commercial Operations for Keryx Biopharmaceuticals, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Keryx Biopharmaceuticals Announces Financial Management Change
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2007
Keryx Biopharmaceuticals Names Beth F. Levine as Senior Vice President, General Counsel & Chief Compliance Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Dec 2006
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Pharmacopeia Announces the Appointment of Vice President, Clinical and Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2006
Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Sep 2006
Medior Announces Completion of Series A Financing Round and Appointment of CEO and Chairman
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 1 Aug 2006
Keryx Biopharmaceuticals Mourns Passing of Board Member Jonathan Spicehandler, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
NephroGenex Licenses Pyridorin(TM) for Diabetic Nephropathy and Acute Renal Failure
Biopharmaceuticals Acquisitions Licensing
 HSMN NewsFeed - 3 Apr 2006
Pharmacopeia Licenses Novel Therapeutic Candidates From Bristol-Myers Squibb
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Mar 2006
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center Study of KRX-0401 for the Treatment of Refractory Leukemia
Biopharmaceuticals
 HSMN NewsFeed - 16 Feb 2006
Keryx Biopharmaceuticals Names Ronald C. Renaud, Jr. as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2006
Keryx Biopharmaceuticals Announces Expansion of Renal Franchise With the In-Licensing of Zerenex(TM), a Novel Phosphate Binder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jan 2006
Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior Pharmaceutical Executive to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2006
Keryx Biopharmaceuticals, Inc. Commences Phase II, Multi-Center Study of KRX-0401 for the Treatment of Refractory Multiple Myeloma
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
diabetic nephropathy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.